Skip to main content

Advertisement

SpringerLink
Log in

The Impact of Pituitary Adenoma on Morbidity

Increased Sick Leave and Disability Retirement in a Cross-Sectional Analysis of Swedish National Data

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Objective: To quantify sick leave and medical retirement for the year 1989 in adults with a history of nonsecreting pituitary adenoma.

Design and Setting: A cross-sectional analysis of official Swedish data from 1989 was performed. Sick leave and disability pension data for these patients were obtained from the Swedish National Social Insurance Board, which also supplied information on sick leave taken by an age- and gender-matched control population of 5121 individuals. Uptake of disability pensions and the reasons for drawing these pensions in the study group were compared with national statistics.

Study Population: A group of 809 eligible adults with nonsecreting pituitary adenoma was identified from the national cancer registry. Main Outcome Measures and Results: Almost a quarter of the patients with a history of pituitary adenoma had retired due to ill health (23.8%); this was twice the figure expected from national statistics (11.5%). Similar results were obtained when men and women were considered separately. Some patients (17%) had received disability pensions before the diagnosis of pituitary adenoma, but the majority (75%) retired on medical grounds at least 1 year after their diagnosis. The reasons for early retirement in the study group were largely related to the diagnosis of pituitary adenoma (e.g. neoplasm, endocrine disorders), but there was some evidence of an increase in the number of disability pensions awarded because of diseases of the nervous system and sensory organs. Patients with a history of pituitary adenoma took significantly more sick leave in 1989 than those in the control group (mean 40.2 vs 24.0 days), and this significant difference applied to both sexes.

Conclusions: A cross-sectional analysis of Swedish national data from 1989 showed excess morbidity, relative to reference data, in patients with a history of nonsecreting pituitary adenoma. Suboptimal conventional hormone replacement therapy and untreated growth hormone deficiency might to some extent explain the increased morbidity found in the present study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Sönksen PH. Replacement therapy in hypothalamo-pituitary insufficiency after childhood: management in the adult. Horm Res 1990; 33 Suppl. 4: 45–51

    Google Scholar 

  2. Hakkaart-van Roijen L, Beckers A, Stevenaert A, et al. The burden of hypopituitarism in adults after pituitary surgery. Endocrinol Metab 1997; 4 Suppl. B: 139–42

    Google Scholar 

  3. Rosén T, Bengtsson B-Å. Epidemiology of adult onset hypopituitarism in Göteborg, Sweden during 1956–1993 [abstract]. 10th International Congress of Endocrinology: 1996 Jun 12- 15; San Francisco: 244

  4. Nilsson B, Gustavsson-Kadaka E, Bengtsson BÅ, et al. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival and mortality. J Clin Endocrinol Metab 2000. In press

  5. Hakkaart-van Roijen L, Beckers A, Stevenaert A, et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998; 14 (4): 395–403

    Article  PubMed  CAS  Google Scholar 

  6. Cuneo RC, Salomon F, McGauley GA, et al. The growth hormone deficiency syndrome in adults. Clin Endocrinol 1992; 37: 387–97

    Article  CAS  Google Scholar 

  7. Binnerts A, Deurenberg P, Swart GR, et al. Body composition in growth hormone-deficient adults. Am J Clin Nutr 1992; 55: 918–23

    PubMed  CAS  Google Scholar 

  8. Rosén T, Bosaeus I, Tölli J, et al. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol 1993; 38: 63–71

    Article  Google Scholar 

  9. Rosén T, Hansson T, Granhed H, et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129 (3): 201–6

    PubMed  Google Scholar 

  10. McGauley GA. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand 1989; 356 Suppl.: 70–2

    Article  CAS  Google Scholar 

  11. Rosén T, Wirén L, Wilhelmsen L, et al. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol 1994; 40: 111–6

    Article  Google Scholar 

  12. Rosén T, Eden S, Larson G, et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol 1993; 129: 195–200

    PubMed  Google Scholar 

  13. Johansson JO, Landin K, Tengborn L, et al. High fibrinogen and plasminogen activator inhibitor activity in growth hormonedeficient adults. Arterioscler Thromb 1994; 14: 434–7

    Article  PubMed  CAS  Google Scholar 

  14. Markussis V, Beshyah SA, Fisher C, et al. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults. Lancet 1992; 340: 1188–92

    Article  PubMed  CAS  Google Scholar 

  15. Rosén T, Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8

    Article  PubMed  Google Scholar 

  16. Bülow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 46: 75–81

    Article  Google Scholar 

  17. Carroll PV, Christ EM, Bengtsson BA, Growth Hormone Research Society Scientific Committee, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83 (2): 382–95

    Google Scholar 

  18. World Health Organization. International classification of diseases: manual of the international statistical classification of diseases, injuries, and causes of death based on the recommendations of the seventh revision conference, 1955, and adopted by the ninth World Health Assembly under the WHO nomenclature regulations. Geneva: World Health Organization, 1955

    Google Scholar 

  19. The National Social Insurance Board. Disability pensions: cost and number of reimbursed pensioners in December 1989 [in Swedish]. Riksförsäkringsverket 1990; I: 6

    Google Scholar 

  20. The National Social Insurance Board. Diseases causing disability pension among disability pensioners in December 1991 [in Swedish]. Riksförsäkringsverket 1995; R: 2

  21. Levene H. In: Olkin I, Ghurye SG, Hoeffding W, et al., editors. Contributions to probability and statistics: essays in honor of Harold Hotelling. Stanford (CA): Stanford University Press, 1960: 278–92

  22. Satterthwaite FE. An approximative distribution of estimates of variance components. Biometrics 1946; 2: 110–4

    Article  PubMed  CAS  Google Scholar 

  23. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture frequency in adult patients with hypopituitarism. Eur J Endocrinol 1997; 137: 240–5

    Article  PubMed  Google Scholar 

  24. Eriksen TE. Rising sickness absence: a statistical analysis [in Swedish]. The National Social Insurance Board. Rapport 1980: 1

    Google Scholar 

  25. Thorner MO, Vance ML, Horvath E, et al. The anterior pituitary. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia (PA): WB Saunders Company, 1992: 221–310

  26. Bengtsson B-Å, Eden S, Lönn L, et al. Treatment of adults with growth hormone deficiency with recombinant human growth hormone. J Clin Endocrinol Metab 1993; 76: 309–17

    Article  PubMed  CAS  Google Scholar 

  27. Mårdh G, Lundin K, Borg G, et al. Growth hormone replacement therapy in adult hypopituitary patients with growth hormone deficiency: combined data from 12 European placebo-controlled clinical trials. Endocrinol Metab 1994; 1 Suppl. A: 43–9

    Google Scholar 

  28. Johannsson G, Rosén T, Bosaeus I, et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 1996; 81: 2865–73

    Article  PubMed  CAS  Google Scholar 

  29. Attanasio AF, Lamberts SWJ, Matranga AMC, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during humanGHtreatment. J Clin Endocrinol Metab 1997; 82: 82–8

    Article  PubMed  CAS  Google Scholar 

  30. Kann P, Piepkorn B, Schehler B, et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol 1998; 48: 561–8

    Article  CAS  Google Scholar 

  31. al-Shoumer KA, Gray R, Anyaoku V, et al. Effect of four years’ treatment with biosynthetic human growth human (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 1998; 48: 795–802

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Göran Mårdh, MD, PhD, for his advice and assistance during the preparation of the manuscript. Pharmacia & Upjohn financially supported this study.

Author information

Authors and Affiliations

  1. Department of Women and Child Health, Karolinska Institute, Stockholm, Sweden

    Björn Jonsson

  2. Department of Cancer Epidemiology, Karolinska University Hospital, Stockholm, Sweden

    Bo Nilsson

Authors
  1. Björn Jonsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bo Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Björn Jonsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jonsson, B., Nilsson, B. The Impact of Pituitary Adenoma on Morbidity. Pharmacoeconomics 18, 73–81 (2000). https://doi.org/10.2165/00019053-200018010-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018010-00008

Keywords

Search

Navigation